Prognosis
Lilly Presents Trial Data on Alzheimer Drug Showing Promise
- Donanemab slowed decline by 32% over 18-month trial period
- Drugmaker presents details of data first released in January
This article is for subscribers only.
Eli Lilly & Co. presented highly anticipated details from a mid-stage study showing that its experimental drug modestly slowed Alzheimer’s disease progression over about 18 months.
The study of 257 patients with early Alzheimer’s showed that Lilly’s donanemab slowed decline by 32% on a composite measure of cognition and function when compared to a placebo. It also completely removed an Alzheimer’s-associated protein from the brains of the majority of patients who received it.